Signaling pathways as therapeutic targets in biliary tract cancer. (4th May 2017)

• Record Type: Journal Article
• Authors: Yang, Jennifer; Farren, Matthew R.; Ahn, Daniel; Bekaii-Saab, Tanios; Lesinski, Gregory B.
• Is Part Of: Expert opinion on therapeutic targets. Volume 21:Number 5(2017:May)
• Page Start: 485
• Page End: 498
• Publication Date: 2017-05-04
• Subjects: Biliary tract cancer -- cholangiocarcinoma -- targeted therapy -- STAT3 -- PI3K -- MEK; Drugs -- Research -- Periodicals; 615.072
• DOI: 10.1080/14728222.2017.1306055
• Languages: English
• ISSNs: 1744-7631

Abstract

ABSTRACT: Introduction : The incidence of biliary tract cancer (BTC) is increasing, and the disease is frequently diagnosed during advanced stages, leading to poor overall survival. Limited treatment options are currently available and novel therapeutic approaches are needed. A number of completed clinical trials have evaluated the role of chemotherapy for BTC, demonstrating a marginal benefit. Thus, there is increased interest in applying targeted therapies for this disease. Areas covered : This review article summarizes the role of chemotherapeutic regimens for the treatment of BTC, and highlights key signal transduction pathways of interest for targeted inhibition. Of particular interest are the MEK or MAP2K (mitogen-activated protein kinase kinase), phosphatidylinositol-3 kinase (PI3K) and signal transducer and activator of transcription-3 (STAT3) pathways. We discuss the available data on several promising inhibitors of these pathways, both in the pre-clinical and clinical settings. Expert opinion : Future treatment strategies should address targeting of MEK, PI3K and STAT3 for BTC, with a focus on combined therapeutic approaches.